Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference - WECT, weather & sports Wilmington, NC

Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE Bioniche Life Sciences Inc.

BELLEVILLE, ON, June 13, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) - ("Bioniche" or the "Company"), a clinical stage biotechnology company whose anchor product is a Phase III treatment for non-muscle-invasive bladder cancer, today announced that Dr. Michael Berendt, Chief Executive Officer and Chief Scientist of Bioniche Life Sciences Inc., will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18, 2014 at 3:30 P.M. EDT in Toronto.  Bioniche's corporate presentation will be available on the Company's website at following the presentation.

Bloom Burton's third annual healthcare investor conference features Canada's premier publicly-traded and venture-backed private companies. The event will attract Canadian, U.S. and European investors who are interested in the latest developments in Canadian healthcare companies.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a clinical stage Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative therapies for the global human health market.  The Company's primary goal is to develop and commercialize products that advance human health and increase shareholder value. For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow